Thuy Do, MD
Family Medicine · Seattle, WANPI 1124336797
Payments from drug & device makers
Across 49 payments — averaging $33.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$508
- AstraZeneca$339
- Kowa Pharmaceuticals America, Inc.$124
- GSK$93
- Gilead$78
- Amgen$69
- plus $409 from 11 others
What the payments were for
- Food & beverage$1,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 9 | $508 |
| AstraZeneca | 10 | $339 |
| Kowa Pharmaceuticals America, Inc. | 6 | $124 |
| GSK | 1 | $93 |
| Gilead | 4 | $78 |
| Amgen | 3 | $69 |
| Edwards Lifesciences | 2 | $58 |
| Exact Sciences | 2 | $55 |
| Novo Nordisk | 2 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Lundbeck LLC | 2 | $46 |
| Lilly USA, LLC | 1 | $33 |
| Dexcom, Inc. | 1 | $32 |
| Pfizer | 1 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Neuronetics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,619 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 69 | $77,641 |
| RybelsusSemaglutide | 38 | $53,337 |
| SynjardyEmpagliflozin/Metformin Hcl | 49 | $38,829 |
| JardianceEmpagliflozin | 19 | $23,491 |
| OzempicSemaglutide | 17 | $23,086 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 20 | $17,478 |
| Spiriva HandihalerTiotropium Bromide | 23 | $16,856 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $14,780 |
| KerendiaFinerenone | 17 | $12,988 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,411 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,881 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,918 |
| Atorvastatin Calcium | 284 | $1,847 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 12 | $1,513 |
| Novolog FlexpenInsulin Aspart | 11 | $1,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $339 | $83,52188 claims |
| Boehringer IngelheimSynjardy, Jardiance, Trijardy Xr | $25 | $79,79888 claims |
| Novo NordiskRybelsus, Ozempic | $50 | $76,42355 claims |
| BayerKerendia | $508 | $12,98817 claims |
| GSKTrelegy Ellipta | $93 | $7,41112 claims |
| Lilly USA, LLCHumulin 70-30 | $33 | $1,51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Seattle
- Emily ZaragozaSeattle$1.9M
- Kevin HatfieldSeattle$527K
- Michelle KarunaSeattle$271K
- Robert McIntyreSeattle$107K
- Emily GodfreySeattle$98K
- Christopher ShuhartSeattle$56K
- Ian BennettSeattle$41K
- Betsy BrownSeattle$23K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.